Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Astrocytoma × Valacyclovir × Clear all

Phase

Phase 2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Prostatic Neoplasms 3 Leukemia 2 Waldenstrom Macroglobulinemia 1 Uveal Melanoma 1 Triple Negative Breast Neoplasms 1 Stomatitis 1 Neoplasms 1 Neoplasm Metastasis 1 Melanoma 1 Lung Neoplasms 1 Leukemia, Lymphocytic, Chronic, B-Cell 1 Head and Neck Neoplasms 1 Glioma 1 Glioblastoma 1 Epstein-Barr Virus Infections 1 Cytomegalovirus Infections 1 Carcinoma, Non-Small-Cell Lung 1 Astrocytoma 1 Adenocarcinoma 1

Interventions

Temozolomide 34 Radiotherapy 15 Bevacizumab 13 Magnetic Resonance Spectroscopy 9 Carmustine 9 antineoplaston AS 2-1 8 antineoplaston A10 8 Carboplatin 8 Irinotecan 7 Filgrastim 5 Cyclophosphamide 5 sargramostim 4 Surgical Procedures, Operative 4 Specimen Handling 4 Everolimus 4 Etoposide 4 Cisplatin 4 trametinib 3 Vincristine 3 Thalidomide 3 Sunitinib 3 Radiation 3 Procarbazine 3 Peripheral Blood Stem Cell Transplantation 3 Lomustine 3 FANG vaccine 3 dabrafenib 2 cabozantinib 2 aldesleukin 2 Topotecan 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00589875 2024-04-03

BrTK02

Candel Therapeutics, Inc.

Phase 2 Completed

52 enrolled 10 charts

Astrocytoma, Glioblastoma, Glioma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡